DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
TEPEZZA Has Resumed Production – FAQ
Horizon Therapeutics, the developer of TEPEZZA, prepared this document to address questions from the Thyroid Eye Disease (TED) community about the resumed production of TEPEZZA, a medicine for TED. Patients can now schedule their infusions. Read on for information about how to schedule infusions, insurance considerations and answers to other frequently asked questions.
Note: If you choose to share or post these FAQs, please share the full document and not select pieces of it, in order to comply with regulatory guidelines.
Questions about TEPEZZA? Talk to Horizon Patient Services.
Call 1-833-469-8331, Mon-Fri, 8 AM – 8 PM EST.
Horizon Patient Services does not provide individual patient care or medical advice.
News & MeetingsHorizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth DriversHorizon Therapeutics plc announced today...
News & MeetingsClinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
Evidence & EducationTeprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid eye D...Thyroid eye disease is a disabling autoi...
News & MeetingsMeeting of Dermatologic and Ophthalmic Drugs Advisory Committee AnnouncementThe committee will discuss biologics lic...
News & MeetingsIntegrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effect...Horizon Therapeutics plc today announced...
News & MeetingsTEPEZZA Short-Term Supply Disruption FAQHorizon Therapeutics plc announced that ...
News & MeetingsThyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.